Product has been added to your cart.
Contact
  1. Home
  3. Cells
  5. Central Nervous System Cells

iPSC derived CNS cells

Neurodegenerative diseases constitute a substantial financial, medial and social burden to populations around the world. With an aging population, this is set to increase.

As a result, neurodegenerative disease is a major focus in drug discovery and research. with Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) being three of the major study areas

iPSC technology enables a scalable source of cells derived from both healthy / control and patient / disease state donors for research and drug discovery.

Axol’s central nervous system (CNS) cells are derived from integration-free, human induced pluripotent stem cells (iPSCs) under fully defined neural induction conditions.

Select cells from healthy donors or from patients with Alzheimer’s disease or Huntington’s disease – including specific mutation variants.

Our human iPSC derived neural stem cells and glial cells

Generate a spectrum of cerebral cortical excitatory and inhibitory neurons from these neural stem cells (NSCs) that are electrically active that can form functional synapses and circuits in vitro. NSCs express typical markers of cerebral cortical neural stem and progenitor cells that include PAX6, FOXG1, and nestin.

Accurately model neurological disorders using these hiPSC-derived neural stem cells (NSCs) from patients with distinct genetic mutations. NSCs express typical markers of cerebral cortical neural stem and progenitor cells that include PAX6, FOXG1, and nestin.

Use human iPSC-derived astrocytes alone or in co-culture to study a range of neurological conditions or complex CNS circuitry. Astrocytes express glial markers that include glial fibrillary acidic protein (GFAP), S100b, AQP4, ALDHL1L, and EAAT1.

Research immune function within the CNS using cryopreserved hiPSC-derived microglia. Cells express typical phenotypic markers three days post-thawing that include CXCR1, TMEM119, IBA-1, and P2RY12.

External references

Researchers citing these products:

Elsworthy, R.J., Crowe, J.A., King, M.C. et al. The effect of citalopram treatment on amyloid-β precursor protein processing and oxidative stress in human hNSC-derived neurons. Transl Psychiatry 12, 285 (2022). https://doi.org/10.1038/s41398-022-02050-5

Ferretti, G., Romano, A., Sirabella, R. et al. An increase in Semaphorin 3A biases the axonal direction and induces an aberrant dendritic arborization in an in vitro model of human neural progenitor differentiation. Cell Biosci 12, 182 (2022). https://doi.org/10.1186/s13578-022-00916-1

Wevers, N.R., Nair, A.L., Fowke, T.M. et al. Modeling ischemic stroke in a triculture neurovascular unit on-a-chip. Fluids Barriers CNS 18, 59 (2021). https://doi.org/10.1186/s12987-021-00294-9

Protocols & Resources

Let’s talk stem cells

For technical or sales support, get in touch:

  • operations@axolbio.com
  • UK & Europe +44 (0) 131 651 9710
  • USA and North America 1-800-678-AXOL (2965)